0001070081-26-000012
SEC filingQ1 revenue fell 76.8% to $272.6M and operating income dropped 95.4% to $45.0M versus prior year licensing windfalls, yielding a net loss of $2.8M despite 16.5% operating margin from R&D efficiencies.
Revenue of $272.6 million in Q1 FY2026 declined 76.8% from $1.2 billion in the prior-year quarter, primarily because the prior period included significant one-time licensing revenue that has now normalized following upfront recognition. This decline was somewhat mitigated by an increase in net product sales of Sephience, in its first year of launch, partially offset by decreases in net product sales of Emflaza and Translarna. The Translarna sales drop stems from the European Commission's adoption of the CHMP's negative opinion, impacting market access.
Operating income reached $45.0 million, down 95.4% from $970.2 million, yet delivered a solid 16.5% operating margin. This resilience reflects a strategic decrease in research and development expenses, driven by reduced program spending in Global DMD, Gene Therapy, Splicing platform, and Sephience-related development as management focuses resources on differentiated, high-potential programs. Selling, general, and administrative expenses increased, primarily due to costs associated with the Novartis agreement, Upstaza/Kebilidi royalty payments, and new product launches including Sephience sales ramp-up.
The company reported a net loss of $2.8 million, a sharp -100.3% change from $866.6 million profit last year, with diluted EPS at -$0.03 versus $10.04. This shift underscores the return to underlying business performance absent exceptional licensing gains, consistent with historical significant operating losses noted in liquidity discussions.
Cash flow from operations was -$59.0 million, contrasting sharply with $870.1 million prior year, reflecting no recurring milestone inflows and contributing to free cash flow of -$60.2 million after $1.2 million in capital expenditures (down from $1.7 million). Management highlights that costs to fulfill contracts, such as those under the Novartis agreement, do not qualify for capitalization and are expensed as incurred, adding to near-term pressures.
Looking forward, SG&A expenses are expected to rise with commercialization efforts for Sephience and other products, including expanded payroll, infrastructure, commercial operations, and consulting/legal costs. Emflaza faces ongoing generic competition following orphan drug exclusivity expiration, which has already eroded and will continue impacting net product revenue. These dynamics, alongside debt maturities, royalty obligations, and persistent historical losses, emphasize the need for disciplined cost management and pipeline progress to achieve sustained profitability without new milestones.